Capricor Therapeutics Inc.

Company Overview

Capricor Therapeutics, Inc. is a clinical stage biotechnology company focused on developing cell and exosome-based therapeutics and vaccines to treat or prevent a broad range of diseases. Capricor's lead candidate, CAP-1002, is a cell therapy currently in phase 3 clinical trial for treatment of Duchenne muscular dystrophy (DMD). CAP-1002 is an allogeneic product (manufactured from donor heart tissue) and then stored until used. CAP-1002 possesses immunomodulatory, anti-inflammatory, and anti-fibrotic properties.

Capricor Therapeutics' exosome platform program consists of engineered exosomes and exosomes derived from cardiosphere-derived cells (CDCs). The company is developing exosome-based vaccines and therapeutics for infectious, monogenic, and other potential indications. Currently, it is focused on securing investors to bring this program into the clinic.

The company has several collaborations around exosomes with leading institutes, including Johns Hopkins University, the Department of Defense, the U.S. Army Institute of Surgical Research, the National Institutes of Health, and Cedars-Sinai Medical Center.

Financial Highlights (FY 2024)

Company's Business Segments

• Transformative Cell and Exosome-based Therapeutics : The company develops transformative cells and exosome-based therapeutics to treat and prevent muscular dystrophy and other select diseases such as Duchenne muscular dystrophy (DMD).